| __timestamp | Neurocrine Biosciences, Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 4167274 |
| Thursday, January 1, 2015 | 33800000 | 5247851 |
| Friday, January 1, 2016 | 35900000 | 4925118 |
| Sunday, January 1, 2017 | 1254000 | 14930297 |
| Monday, January 1, 2018 | 4889000 | 25371768 |
| Tuesday, January 1, 2019 | 7400000 | 23921274 |
| Wednesday, January 1, 2020 | 10100000 | 25338236 |
| Friday, January 1, 2021 | 14300000 | 20182966 |
| Saturday, January 1, 2022 | 23200000 | 17562000 |
| Sunday, January 1, 2023 | 39700000 | 25212000 |
| Monday, January 1, 2024 | 34000000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. Over the past decade, Neurocrine Biosciences, Inc. and Pharming Group N.V. have demonstrated contrasting trends in their cost of revenue. From 2014 to 2023, Neurocrine Biosciences saw a significant increase in cost efficiency, with their cost of revenue peaking at approximately 39.7 million in 2023, a remarkable 175% increase from 2014. In contrast, Pharming Group N.V. experienced a more stable trajectory, with costs rising steadily to about 25.2 million in 2023, marking a 505% increase from 2014. This divergence highlights Neurocrine's aggressive growth strategy, while Pharming maintains a more consistent approach. As the biotech industry evolves, understanding these financial dynamics is crucial for investors and stakeholders aiming to make informed decisions.
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Eli Lilly and Company vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: AbbVie Inc. vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Pharming Group N.V.
Cost of Revenue Trends: Teva Pharmaceutical Industries Limited vs Pharming Group N.V.
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Telix Pharmaceuticals Limited
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Pharming Group N.V.
Analyzing Cost of Revenue: Catalent, Inc. and Pharming Group N.V.
Cost Insights: Breaking Down Pharming Group N.V. and Corcept Therapeutics Incorporated's Expenses